Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global E Online Ltd (GLBE) vs Nuvalent Inc (NUVL) Price & Performance

Global E Online LtdTrade
Nuvalent IncTrade

Price performance (Past 24H)

Key statistics

Global E Online Ltd vs Nuvalent Inc — how do they compare? Global E Online Ltd trades at $38.32 (market cap $6.55B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Nuvalent Inc is the larger of the two by market cap, and Nuvalent Inc is trading nearer its 52-week high, Global E Online Ltd nearer its low. Which is the better fit depends on your goals.

GLBENUVL
Market Cap
$6.55B$9.81B
Sector
TechnologyTechnology
52-Week High
$41.59$123.96
52-Week Low
$27.54$72.16
Enterprise Value
$6.02B$8.52B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global E Online Ltd

GLBE trades at $38.43, down 0.84% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with 33% revenue growth and raised its full-year outlook. Recent acquisition of Passport aims to enhance logistics capabilities. Valuation ratios are elevated with a P/E of 58.18, reflecting high growth expectations.

Outlook remains positive driven by merchant expansion and cross-border e-commerce growth, but high valuation poses a risk if growth slows. Analyst consensus is unanimously bullish with a $38 price target, though recent insider sales and mixed quarterly EPS performance warrant monitoring.

Nuvalent Inc

Nuvalent (NUVL) trades at $123.96, unchanged on the day, with a P/B ratio of 8.35 and negative profitability metrics. The stock is technically bullish based on moving averages, though oscillators are neutral. Recent news highlights GSK's proposed acquisition of Nuvalent for $124 per share, totaling $10.6 billion, announced on June 9, 2026 (Reuters). Earnings have been mixed, with two misses and one beat in the last three quarters.

The acquisition by GSK provides a near-term price floor but limits upside. Risks include ongoing financial losses and shareholder litigation questioning deal fairness. Analyst sentiment is mixed with 42% buy ratings. The stock's outlook hinges on deal completion, with fundamental challenges persisting until closure.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Global E Online Ltd

Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.

Read more on GLBE

About Nuvalent Inc

Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.

Read more on NUVL